A new study on the economic benefits of pneumococcal conjugate vaccination (PCV) has found that current vaccine pricing policies disproportionately benefit high-income countries and manufacturers. Over the two decades of PCV availability, low- and middle-income countries (LMICs) have not received the full economic benefits of PCV. Early adoption of appropriate pooled procurement mechanisms, promoting vaccine manufacturing in LMICs and more steeply tiered prices, especially in MICs, could promote greater vaccine access outside Gavi and PAHO members.
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.